Feet P O, Larsen S, Robak O H
Acta Psychiatr Scand. 1985 Oct;72(4):334-40. doi: 10.1111/j.1600-0447.1985.tb02618.x.
Sixty-three out-patients suffering from primary non-agitated depression were included in a double-blind, between-patient randomized study. All patients were treated with imipramine (100-200 mg-day) combined with either placebo, diazepam (10 mg/day) or dixyrazine (50 mg/day) for 8 weeks. The clinical efficacy assessed with a subscale of CPRS was significantly (p1 less than or equal to 0.05) better for the imipramine-dixyrazine combination than for the imipramine-diazepam or imipramine-placebo combination. Serum concentration of imipramine was significantly higher (p1 less than or equal to 0.05) in the group treated with dixyrazine than in the other two groups. Further, serum concentration of imipramine in the diazepam group was significantly lower (p1 less than or equal to 0.05) than in the placebo group. At the end of the study, 67% in both the placebo and the diazepam group and 86% in the dixyrazine group were practically symptom-free.
63名患有原发性非激越性抑郁症的门诊患者被纳入一项双盲、患者间随机研究。所有患者均接受丙咪嗪（100 - 200毫克/天）治疗，同时分别联合使用安慰剂、地西泮（10毫克/天）或二苯西平（50毫克/天），为期8周。使用临床疗效评定量表（CPRS）的一个子量表评估发现，丙咪嗪 - 二苯西平联合用药组的临床疗效显著（p1≤0.05）优于丙咪嗪 - 地西泮联合用药组或丙咪嗪 - 安慰剂联合用药组。接受二苯西平治疗的组中丙咪嗪的血清浓度显著高于（p1≤0.05）其他两组。此外，地西泮组中丙咪嗪的血清浓度显著低于（p1≤0.05）安慰剂组。研究结束时，安慰剂组和地西泮组中67%的患者以及二苯西平组中86%的患者几乎没有症状。
